Wolfgang Vanscheidt

Summary

Country: Germany

Publications

  1. ncbi request reprint The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study
    W Vanscheidt
    Dermatologic Clinic, University Freiburg, Germany
    Vasa 31:185-90. 2002
  2. ncbi request reprint Dose-response of compression therapy for chronic venous edema--higher pressures are associated with greater volume reduction: two randomized clinical studies
    Wolfgang Vanscheidt
    Dermatologische Praxisgemeinschafts, Freiburg, Germany
    J Vasc Surg 49:395-402, 402.e1. 2009
  3. ncbi request reprint [Systematic management of chronic wounds employing the TIME concept]
    W Vanscheidt
    Dermatologische Praxisgemeinschaft Freiburg
    MMW Fortschr Med 147:119-26. 2005
  4. doi request reprint Effectiveness and tissue compatibility of a 12-week treatment of chronic venous leg ulcers with an octenidine based antiseptic--a randomized, double-blind controlled study
    Wolfgang Vanscheidt
    Int Wound J 9:316-23. 2012
  5. ncbi request reprint Treatment of recalcitrant venous leg ulcers with autologous keratinocytes in fibrin sealant: a multinational randomized controlled clinical trial
    W Vanscheidt
    Dermatologische Praxisgemeinschaft Freiburg, Freiburg, Germany
    Wound Repair Regen 15:308-15. 2007
  6. ncbi request reprint A prospective study on the use of a non-adhesive gelling foam dressing on exuding leg ulcers
    W Vanscheidt
    Dermatologische Gemeinschaftspraxis, University Freiburg, Germany
    J Wound Care 16:261-5. 2007
  7. ncbi request reprint Enzymatic versus autolytic debridement of chronic leg ulcers: a prospective randomised trial
    M Konig
    Dermatology Praxis, Gundelfingen, Germany
    J Wound Care 14:320-3. 2005
  8. ncbi request reprint Treatment of therapy-refractive ulcera cruris of various origins with autologous keratinocytes in fibrin sealant
    S Johnsen
    Department of Dermatology, University Hospital Freiburg, Germany
    Vasa 34:25-9. 2005
  9. ncbi request reprint Short-stretch versus multilayer compression for venous leg ulcers: a comparison of healing rates
    A Ukat
    Department of Dermatology, University Hospital of Freiburg, Freiburg, Germany
    J Wound Care 12:139-43. 2003
  10. ncbi request reprint [Cost effectiveness of treating skin grafts with a special hydrogel formulation]
    M Augustin
    SG Gesundheitsökonomie Klinik für Dermatologie und Venerologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg
    MMW Fortschr Med 147:60. 2005

Collaborators

Detail Information

Publications15

  1. ncbi request reprint The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study
    W Vanscheidt
    Dermatologic Clinic, University Freiburg, Germany
    Vasa 31:185-90. 2002
    ....
  2. ncbi request reprint Dose-response of compression therapy for chronic venous edema--higher pressures are associated with greater volume reduction: two randomized clinical studies
    Wolfgang Vanscheidt
    Dermatologische Praxisgemeinschafts, Freiburg, Germany
    J Vasc Surg 49:395-402, 402.e1. 2009
    ..The objective of each study was to evaluate the safety and the relative effects of different cuff pressure combinations to determine if edema reduction was dose-dependent...
  3. ncbi request reprint [Systematic management of chronic wounds employing the TIME concept]
    W Vanscheidt
    Dermatologische Praxisgemeinschaft Freiburg
    MMW Fortschr Med 147:119-26. 2005
    ..The present article discusses the principles and scientific background to this TIME concept...
  4. doi request reprint Effectiveness and tissue compatibility of a 12-week treatment of chronic venous leg ulcers with an octenidine based antiseptic--a randomized, double-blind controlled study
    Wolfgang Vanscheidt
    Int Wound J 9:316-23. 2012
    ..OHP is well suitable for the treatment of chronic wounds without cytotoxic effects. Furthermore, OHP does not impair the wound healing in chronic venous ulcers...
  5. ncbi request reprint Treatment of recalcitrant venous leg ulcers with autologous keratinocytes in fibrin sealant: a multinational randomized controlled clinical trial
    W Vanscheidt
    Dermatologische Praxisgemeinschaft Freiburg, Freiburg, Germany
    Wound Repair Regen 15:308-15. 2007
    ..0001). This study, to date the largest multicenter study with autologous keratinocytes, provides evidence for its efficacy in the treatment of patients with therapy-resistant chronic venous leg ulcers...
  6. ncbi request reprint A prospective study on the use of a non-adhesive gelling foam dressing on exuding leg ulcers
    W Vanscheidt
    Dermatologische Gemeinschaftspraxis, University Freiburg, Germany
    J Wound Care 16:261-5. 2007
    ..This non-comparative phase II study aimed to evaluate the safety and performance of a non-adhesive gelling foam dressing (GFD-N) in leg ulcer management...
  7. ncbi request reprint Enzymatic versus autolytic debridement of chronic leg ulcers: a prospective randomised trial
    M Konig
    Dermatology Praxis, Gundelfingen, Germany
    J Wound Care 14:320-3. 2005
    ....
  8. ncbi request reprint Treatment of therapy-refractive ulcera cruris of various origins with autologous keratinocytes in fibrin sealant
    S Johnsen
    Department of Dermatology, University Hospital Freiburg, Germany
    Vasa 34:25-9. 2005
    ..Evaluation of the effects of cultivated, subconfluent, autologous keratinocytes in fibrin sealant (BioSeed-S) on the healing of therapy-refractive chronic wounds...
  9. ncbi request reprint Short-stretch versus multilayer compression for venous leg ulcers: a comparison of healing rates
    A Ukat
    Department of Dermatology, University Hospital of Freiburg, Freiburg, Germany
    J Wound Care 12:139-43. 2003
    ..To compare the performance of two compression systems, (multilayer elastic [Profore], Smith and Nephew) and (short stretch [Comprilan], Beiersdorf), in the treatment of venous leg ulcers in a randomised controlled trial...
  10. ncbi request reprint [Cost effectiveness of treating skin grafts with a special hydrogel formulation]
    M Augustin
    SG Gesundheitsökonomie Klinik für Dermatologie und Venerologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg
    MMW Fortschr Med 147:60. 2005
  11. ncbi request reprint Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers
    J Norgauer
    Department of Dermatology, University Medical Center, Hauptstrasse 7, D 79104 Freiburg, Germany
    Br J Dermatol 147:1180-6. 2002
    ..Extracellular MMP inducer (EMMPRIN; CD147) has been reported to increase MMP expression, and membrane type 1 MMP (MT1-MMP) has been implicated in the activation of MMPs...
  12. ncbi request reprint [Compression therapy of venous varicose ulcer. New bandage saves time and money]
    A Ukat
    Rheintalklinik, Thürachstr 10, D 79189 Bad Krozingen
    MMW Fortschr Med 144:41. 2002
  13. ncbi request reprint Late manifestation of dyskeratosis congenita presenting as chronic dermal ulcer in a 37-year-old man
    C Reimann
    J Eur Acad Dermatol Venereol 22:897-8. 2008
  14. ncbi request reprint Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation
    Y Herouy
    Department of Dermatology, University Hospital, Freiburg, Germany
    J Invest Dermatol 111:822-7. 1998
    ..Furthermore, MMP-2 was imbalanced by locally reduced expression of TIMP-2 in the basement membrane zone of lesional skin. Our findings indicate lipodermatosclerosis to be characterized by elevated matrix turnover...
  15. ncbi request reprint Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases
    J C Simon
    Department of Dermatology, University of Freiburg, Germany
    J Invest Dermatol 103:539-43. 1994
    ..We speculate that "alternative" T cell-activation via the B7/CD28 pathway may contribute to the pathogenesis of these skin diseases...